

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



瑋俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

**SUPPLEMENTAL ANNOUNCEMENT
IN RELATION TO CHANGE OF AUDITOR**

Reference is made to the announcements of Wai Chun Bio-Technology Limited (the “**Company**”) dated 26 July 2024 and 29 July 2024 regarding the Change of Auditor (the “**Announcements**”). Capitalised terms used herein shall have the same meanings as those defined in the Announcements unless the context requires otherwise.

The board (the “**Board**”) of the directors (the “**Directors**”) of the Company would like to supplement that the reasons for the resignation of CCTH CPA Limited (“**CCTH**”) as the auditor of the Company being the Company could not reach an agreement with CCTH on the auditor’s remuneration for the year ended 30 June 2024.

Saved as disclosed above, all other information as set out in the Announcements remain unchanged and shall continue to be valid for all purposes. This announcement is supplemental to and should be read in conjunction with the Announcements.

By order of the Board
Wai Chun Bio-Technology Limited
LAM KA CHUN
Executive Director

Hong Kong, 21 August 2024

As at the date of this announcement, the Board consists of one executive Director, namely Mr. Lam Ka Chun and two independent non-executive Directors, namely Mr. Wan Bo and Mr. HE Tao.